<DOC>
	<DOCNO>NCT02329743</DOCNO>
	<brief_summary>The primary objective study assess efficacy safety 2 concentration RX-10045 ophthalmic solution , 0.05 % 0.1 % , compare placebo treatment ocular inflammation pain subject undergoing cataract surgery .</brief_summary>
	<brief_title>Efficacy Safety RX-10045 Ophthalmic Solution Ocular Inflammation Pain Cataract Surgery</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Unilateral cataract surgery ( phacoemulsification extracapsular extraction ) posterior chamber intraocular lens implantation capsular bag . Any additional surgical procedure time cataract surgery Refractive surgery study eye within past 2 year History presence noninfectious inflammatory ocular disease ( e.g. , episcleritis , scleritis , uveitis ) either eye Intraocular pressure &gt; 21 mm Hg either eye Proliferative severe nonproliferative diabetic retinopathy either eye Neovascular/wet agerelated macular degeneration either eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>